**Author Information** An event is serious (based on the ICH definition) when the patient outcome is:\* death\* life-threatening\* hospitalisation\* disability\* congenital anomaly\* other medically important event

In a case series, 3 patients (2 men and 1 woman), ages between 49−81 years were described, who exhibited lack of efficacy while being treated with heparin or tinzaparin sodium for pulmonary embolism (PE) or deep vein thrombosis (DVT).

The patients, who were hospitalised due to COVID-19, were found to have venous thromboembolism consisting PE (2 patients) and PE and DVT (1 patient). Out of these 3 patients, 2 patients who had PE, received tinzaparin sodium \[tinzaparin; *routes not stated*\] 175 units/kg. However, both the patients were found to be refractory to tinzaparin sodium treatment. Thus, due to low anti-factor Xa levels, tinzaparin sodium treatment in both was then switched to enoxaparin sodium \[enoxaparin\]. Remaining patient, who had PE and DVT received IV heparin \[*dosage not stated*\]; however, the patient was found to be refractory to heparin. The patient\'s activated partial thromboplastin time ratio was subtherapeutic, thus heparin was switched to argatroban and patient improved clinically.
